Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized open-label study of epcoritamab versus investigator's choice chemotherapy in relapsed or refractory diffuse large B-cell lymphoma
CTR20221558Phase 3Active
- Sponsor
- Genmab US, Inc./ 艾伯维医药贸易（上海）有限公司/ Vetter Pharma-Fertigung GmbH & Co.KG
- Start
- Oct 2022
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of epcoritamab in diffuse large B-cell lymphoma (DLBCL), large-cell lymphoma, follicular lymphoma (FL), T-cell/histiocyte-rich large B-cell lymphoma (THRLBCL), sponsored by Genmab US, Inc./ 艾伯维医药贸易（上海）有限公司/ Vetter Pharma-Fertigung GmbH & Co.KG. Started Oct 2022; status: active.
02
Drugs
epcoritamab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)large-cell lymphomafollicular lymphoma (FL)T-cell/histiocyte-rich large B-cell lymphoma (THRLBCL)
Beyond the preview
Go deeper on CTR20221558.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221558.